ArticleBlood2020

Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia.

Mrinal M Patnaik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.